Listen to The Lancet

A Health Policy piece in our April issue by Tasdik Hasan and co-authors titled: Co-designing a Bangla Mental Health Sign Language Bank in Bangladesh

Can personality disorder treatments be reduced to just a few months?

In this episode, co-hosted by our Senior Editor Amy Slogrove and our Lancet Child & Adolescent Health Youth Advisory Panel member, Matea Canizares, we discuss adolescent digital intimate partner violence.

The uniqueness of each patient is at the heart of this year's World Cancer Day. In this Podcast you will hear from two cancer survivors about their unique experience with cancer and the importance of personalised cancer care not only on their bodies but also on their lives.

In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflecting on London Global Cancer Week 2025.

Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.

Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processed food industry.

Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.

Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.

Walter Willett, Shakuntala Thilsted and Johan Rockström discuss the second EAT- Lancet Commission report.

Stephen Chan joins Ben Abbott of The Lancet to discuss the key messages of the Lancet  Commission on addressing the global hepatocellular carcinoma burden, which is published today on World Hepatitis Day.

Rebecca Fitzgerald joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett’s oesophagus surveillance in the UK.

Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer.

Francis Couturaud joins Chloe Wilson of The Lancet to discuss the RENOVE trial, which looks at assessing the efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated.

Donald Trump has taken office in the US and immediately turned his attention to dismantling the US position as a world leader in global health. How will actions taken so far affect the health of people around the world? Gavin is joined by co-host Miriam Sabin, North American Executive Editor at The Lancet , and they speak to Dr. Gavin Yamey, lead author of The Lancet' s recent Commission on Invest...

Michael Heneka joins Chloe Wilson and Bea Gomez Perez-Nievas of The Lancet to discuss a therapeutics paper discussing the opportunities and challenges of passive anti-amyloid β immunotherapy in Alzheimer's disease.

ROSHNI-2 was a multicentre, randomised controlled trial that investigated the efficacy of a culturally adapted, cognitive behavioural therapy-based intervention for postnatal depression in British south Asian women. Joining us to share their expertise and perspectives are chief investigator Professor Nusrat Husain, trial manager Farah Lunat, and service user representative Fehmida Motala.

Rasha Al-Lamee and Shayna Chotai join Chloe Wilson of The Lancet to discuss ESC Congress 2024 highlights.

Gavin is joined by Paul Moran and Helen Christensen to discuss The Lancet' s new commission on self-harm, exploring its prevalence, cultural factors, and the crucial need for better data and compassionate care. We also talk about stigma and improving mental health services globally.

On August 14th, the World Health Organisation declared a public health emergency of international concern in relation to mpox. This was motivated, in part, by the emergence of a concerning new strain of mpox, clade 1b, which has spread rapidly across Central Africa. Joining Callam Davidson from  The Lancet  to discuss important clinical aspects of the current mpox outbreak are Dr Oriol M...

Natasha Pocovi joins Chloe Wilson of The Lancet to discuss a trial investigating a walking and education intervention for the prevention of low back pain recurrence in Australia (WalkBack).

14 modifiable risk factors account for 49% of dementia cases worldwide. Gavin and Jessamy are joined by Prof. Gill Livingston (UCL) and Prof. Geir Selbaek (University of Oslo) to discuss the 2024 updates to The Lancet Commission on dementia prevention.

What are the hidden costs of breast cancer? What advances in breast cancer treatment have been made, and how can we tackle the problematic inequities that remain? What needs to be done for patients with metastatic breast cancer? Gavin and Jessamy are joined by Felicia Knaul, Reshma Jagsi, and Fatima Cardoso to discuss the recent Lancet Breast Cancer Commission.

Prasad Kulkarni joins Callam Davidson of The Lancet to discuss the safety and immunogenicity of a bivalent conjugate vaccine against typhoid and paratyphoid, following the publication of a phase 1 trial.